Two men lose RM470k to investment and phone scams in Ipoh
Ipoh police chief ACP Abang Zainal Abidin Abang Ahmad said the first victim, a site supervisor, was lured by a Facebook advertisement for 'KKR Investment,' which promised returns of 10 to 20 per cent within a short period.
'Enticed by the offer, the supervisor made 14 transactions to six different bank accounts between April and July, only to realise he had been scammed when he was asked to make additional payments supposedly for profit withdrawal,' he said.
In the second case, a 56-year-old former factory worker lost RM166,897.58 after receiving a call from someone posing as a Malaysian Communications and Multimedia Commission (MCMC) officer in June.
Abang Zainal Abidin said the scammer claimed the victim's phone number was linked to illegal moneylending activities and pressured him to file a police report.
'The victim was then connected to another individual pretending to be a Bukit Aman police officer, who instructed him to transfer money from his EPF account to a company account for 'investigation purposes,'' he explained.
The transfer was made on July 7 before the victim realised he had been deceived. Police urge the public to be wary of unrealistic investment offers and unsolicited calls from unknown parties. - BERNAMApix
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malay Mail
an hour ago
- Malay Mail
MCMC: Facebook removed leaked meeting clip for breaching content rules
KUALA LUMPUR, July 26 — The Malaysian Communications and Multimedia Commission (MCMC) said that an audio clip, allegedly recorded during an internal meeting and widely circulated online, was removed by Facebook (Meta) for violating the platform's content policies. In a statement yesterday, MCMC said the removal was made entirely based on Meta's community guidelines and content standards. The commission added that monitoring and investigations were initiated following public complaints. 'MCMC takes seriously the act of uploading or sharing audio or video content without consent, especially when it potentially violates privacy, contains offensive material, spreads misinformation, or causes unnecessary distress to those involved. 'We urge all parties to exercise greater caution when sharing content on digital platforms,' the statement read. MCMC further cautioned that the dissemination of unauthorised or provocative content may result in legal action under existing laws, including the Communications and Multimedia Act 1998. — Bernama
New Straits Times
10 hours ago
- New Straits Times
MCMC: Facebook removes viral audio clip for policy violation
KUALA LUMPUR: The Malaysian Communications and Multimedia Commission (MCMC) said that an audio clip, allegedly recorded during an internal meeting and widely circulated online, was removed by Facebook (Meta) for violating the platform's content policies. In a statement today, MCMC said the removal was made entirely based on Meta's community guidelines and content standards. The commission added that monitoring and investigations were initiated following public complaints. "MCMC takes seriously the act of uploading or sharing audio or video content without consent, especially when it potentially violates privacy, contains offensive material, spreads misinformation, or causes unnecessary distress to those involved. "We urge all parties to exercise greater caution when sharing content on digital platforms," the statement read. MCMC further cautioned that the dissemination of unauthorised or provocative content may result in legal action under existing laws, including the Communications and Multimedia Act 1998.
Malaysian Reserve
10 hours ago
- Malaysian Reserve
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
INDIANAPOLIS, July 25, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease. 'This acquisition unlocks the opportunity to potentially transform the treatment paradigm for millions of patients worldwide by delivering lifelong cardiovascular risk reduction with a one-and-done treatment,' said Ruth Gimeno, Lilly group vice president, Diabetes and Metabolic Research and Development. 'We are excited to welcome Verve colleagues to Lilly and work together to develop innovative genetic medicines for cardiometabolic disease.' About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram, and LinkedIn. F-LLY Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements regarding Lilly's acquisition of Verve, regarding prospective benefits of the acquisition and Verve's gene editing programs for cardiovascular disease, regarding Verve's product candidates and ongoing clinical and preclinical development, and regarding Lilly's development of programs for cardiovascular disease and advancement of cardiometabolic health medicines. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements reflect current beliefs and expectations; however, these statements involve inherent risks and uncertainties, including with respect to drug research, development and commercialization, Lilly's evaluation of the accounting treatment of the acquisition and its potential impact on its financial results and financial guidance, regulatory changes and developments, the impact of global macroeconomic conditions, including trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions, risks that the acquisition disrupts current plans and operations or adversely affect employee retention, and any legal proceedings that have been or may be instituted related to the acquisition. Actual results could differ materially due to various factors, risks and uncertainties. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the acquisition, that product candidates will be approved on anticipated timelines or at all, that any products, if approved, will be commercially successful, that all or any of the contingent consideration will become payable on the terms described herein or at all, that Lilly's financial results will be consistent with its expected 2025 guidance or that Lilly can reliably predict the impact of the acquisition on its financial results or financial guidance. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the U.S. Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this press release. Refer to: Ashley Hennessey; gentry_ashley_jo@ 317-416-4363 (Media) Michael Czapar; czapar_michael_c@ 317-617-0983 (Investors)
